FA

CNL STRATEGIC CAPITAL ANNOUNCES OPERATING RESULTS FOR YEAR-END 2023

Retrieved on: 
Thursday, March 28, 2024
FA, Investment, CNL, NAV

Orlando, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- CNL Strategic Capital, LLC (“CNL Strategic Capital,” the “Company” or “we”) seeks to provide current income and long-term appreciation to investors by acquiring controlling equity stakes in combination with loan positions in privately owned middle-market businesses.

Key Points: 
  • Orlando, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- CNL Strategic Capital, LLC (“CNL Strategic Capital,” the “Company” or “we”) seeks to provide current income and long-term appreciation to investors by acquiring controlling equity stakes in combination with loan positions in privately owned middle-market businesses.
  • The Company announced its operating results for the year ended Dec. 31, 2023.
  • For the year ended Dec. 31, 2023, CNL Strategic Capital received approximately $260.0 million in net offering proceeds, including approximately $12.8 million received through the distribution reinvestment plan.
  • Since beginning operations in February 2018 until Dec. 31, 2023, CNL Strategic Capital had raised approximately $909.7 million, including $28.2 million received through the distribution reinvestment plan.

Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, March 19, 2024
Research, Observational study, Cerebellar ataxia, Biotechnology, Gene expression, FXN, Disease, Webcast, Patient, G&A, DM1, Design, IND, Treatment, Clinical trial, Investigational New Drug, Therapy, Completeness, Evaluation, DMPK, FA, HD, Food, FDA, GLP, HTT, Pharmaceutical industry

R&D Expenses: Research and development (R&D) expenses were $11.0 million for the quarter ended December 31, 2023, and $57.1 million for the year ended December 31, 2023.

Key Points: 
  • R&D Expenses: Research and development (R&D) expenses were $11.0 million for the quarter ended December 31, 2023, and $57.1 million for the year ended December 31, 2023.
  • G&A Expenses: General and administrative (G&A) expenses were $4.1 million for the quarter ended December 31, 2023, and $21.1 million for the year ended December 31, 2023.
  • Net Loss: Net loss was $11.8 million for the quarter ended December 31, 2023, and $66.9 million for the year ended December 31, 2023.
  • Cash Position and Operating Runway: Cash, cash equivalents and marketable securities were $281.8 million as of December 31, 2023.

New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia

Retrieved on: 
Friday, March 15, 2024
Patient, Bone marrow failure, CSU, Clinical trial, Therapy, Definitive, CD117, FA

The data was presented at the 2024 Stanford Medicine Center for Definitive and Curative Medicine Symposium on March 13, 2024, in Palo Alto, California.

Key Points: 
  • The data was presented at the 2024 Stanford Medicine Center for Definitive and Curative Medicine Symposium on March 13, 2024, in Palo Alto, California.
  • The ongoing investigator initiated Phase 1b/2a clinical trial is evaluating a conditioning regimen that includes intravenous briquilimab as a potential treatment for FA patients in bone marrow failure.
  • Data from the study show that briquilimab infusion has a promising safety profile and appears to be well tolerated in patients with FA, with all six patients treated achieving full donor engraftment and full blood count recovery.
  • “We’d like thank our collaborators at Stanford Medicine for their work evaluating briquilimab in this vulnerable patient population.”

Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development

Retrieved on: 
Thursday, March 14, 2024
Research, Database, Gene expression, Disease, Patient, Accounting, OLE, Insurance, Ataxia, Clinical trial, Skin, Therapy, Safety, Pharmacokinetics, Interim, FA, FDA, BLA, Pharmaceutical industry

BALA CYNWYD, Pa., March 14, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its fourth quarter and full year 2023 operating and financial results.

Key Points: 
  • BALA CYNWYD, Pa., March 14, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its fourth quarter and full year 2023 operating and financial results.
  • Nomlabofusp was generally well-tolerated and demonstrated dose-dependent increases in skin and buccal cell frataxin levels.
  • Research and development expenses for the fourth quarter of 2023 were $10.6 million compared to $7.2 million for the fourth quarter of 2022.
  • General and administrative expenses for the fourth quarter of 2023 were $3.5 million compared to $3.2 million for the fourth quarter of 2022.

Mitsubishi Electric to Transfer Distribution Transformer Business to Hitachi Industrial Equipment Systems

Retrieved on: 
Friday, April 5, 2024
Technology, Utilities, Manufacturing, Energy, Other Manufacturing, Hardware, Transfer, Electricity, Growth, Mitsubishi Group, Head, Mitsubishi Electric, Industrial, Investment, OT, Power, FA, Hitachi, Electric power

Hitachi Industrial Equipment Systems Co., Ltd. (Head Office: Chiyoda-ku, Tokyo; President and CEO: Yasuhiro Takeuchi; hereinafter “Hitachi Industrial Equipment Systems”) and Mitsubishi Electric Corporation (Head Office: Chiyoda-ku, Tokyo; President & CEO: Kei Uruma; hereinafter “Mitsubishi Electric”) today announced that they have agreed to transfer the distribution transformer business of Mitsubishi Electric’s Nagoya Works, which develops and manufactures factory automation (FA) equipment, to Hitachi Industrial Equipment Systems and integrate their businesses (hereinafter “Business Transfer”).

Key Points: 
  • Hitachi Industrial Equipment Systems Co., Ltd. (Head Office: Chiyoda-ku, Tokyo; President and CEO: Yasuhiro Takeuchi; hereinafter “Hitachi Industrial Equipment Systems”) and Mitsubishi Electric Corporation (Head Office: Chiyoda-ku, Tokyo; President & CEO: Kei Uruma; hereinafter “Mitsubishi Electric”) today announced that they have agreed to transfer the distribution transformer business of Mitsubishi Electric’s Nagoya Works, which develops and manufactures factory automation (FA) equipment, to Hitachi Industrial Equipment Systems and integrate their businesses (hereinafter “Business Transfer”).
  • After obtaining approval from the relevant authorities, assets and other items related to the distribution transformer business (development, design, manufacturing, sales, and maintenance) at Mitsubishi Electric’s Nagoya Works will be transferred to Hitachi Industrial Equipment Systems in stages beginning in October 2024, with completion scheduled for April 1, 2026.
  • The Business Transfer does not include the transformers manufactured at Mitsubishi Electric’s Transmission & Distribution Systems Center, Ako Factory.
  • Through this Business Transfer, Hitachi Industrial Equipment Systems will expand its product lineup of highly energy-efficient and eco-friendly transformers and accelerate the growth of grid edge solutions centered on power distribution systems, mainly in the domestic market.

Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia

Retrieved on: 
Tuesday, April 2, 2024
Biotechnology, Pharmaceutical, Oncology, General Health, Health, Genetics, Clinical Trials, Other Health, Transplant, DNA repair, Medication, Biologics license application, MAA, Risk, FANCA, Patient, Fanconi anemia, Pharming, DNA, BMF, HSCT, EMA, Bone marrow failure, Death, Birth, Life, MBA, European Medicines Agency, Marketing, FA, Disorder, FDA, BLA, Genetic disorder, Food

“The acceptance of the MAA for RP-L102 marks an important step forward in our goal of bringing this potential gene therapy treatment to patients impacted by this devastating childhood disorder.

Key Points: 
  • “The acceptance of the MAA for RP-L102 marks an important step forward in our goal of bringing this potential gene therapy treatment to patients impacted by this devastating childhood disorder.
  • Currently, there are no existing options to potentially prevent BMF for patients with FA,” said Kinnari Patel, Pharm.D., MBA, President, Head of R&D and Chief Operating Officer, Rocket Pharma.
  • The safety profile was highly favorable with no significant safety signals, and the treatment, administered without any cytotoxic conditioning, was well tolerated.
  • The Biologics License Application (BLA) for FA remains on track for submission to the U.S. Food and Drug Administration (FDA) in the first half of 2024.

Mitsubishi Electric and Nozomi Networks to Expand Operational Technology Security Business

Retrieved on: 
Thursday, March 14, 2024
Software, Networks, Other Manufacturing, Hardware, Data Management, Technology, Manufacturing, Security, Mitsubishi Electric, OT, FA, Knowledge, Marketing

Mitsubishi Electric Corporation (TOKYO:6503) announced today that it has reached agreement with Nozomi Networks Inc, a developer and distributor of operational technology (OT) security solutions, to jointly pursue OT security initiatives including marketing and technical development.

Key Points: 
  • Mitsubishi Electric Corporation (TOKYO:6503) announced today that it has reached agreement with Nozomi Networks Inc, a developer and distributor of operational technology (OT) security solutions, to jointly pursue OT security initiatives including marketing and technical development.
  • As part of the agreement, Mitsubishi Electric has acquired an equity stake in Nozomi Networks.
  • Mitsubishi Electric will integrate its factory-automation (FA) equipment and OT security solutions with Nozomi Networks’ OT network-visualization and intrusion-detection technologies to create OT security solutions that enhance both robust security and continuous system operation.
  • Mitsubishi Electric offers one-stop OT security solutions to protect manufacturing sites from cyberattacks.

Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s Ataxia

Retrieved on: 
Monday, March 11, 2024
Pharmacology, Friedreich's ataxia, FDA, BLA, Ataxia, Mitochondrion, Safety, Therapy, Pharmacokinetics, Patient, OLE, FA, Gene expression, Pharmaceutical industry

Nomlabofusp (CTI-1601) is a novel protein replacement therapy designed to address the root cause of Friedreich's ataxia (FA) by delivering frataxin to mitochondria.

Key Points: 
  • Nomlabofusp (CTI-1601) is a novel protein replacement therapy designed to address the root cause of Friedreich's ataxia (FA) by delivering frataxin to mitochondria.
  • “We are pleased to dose the first patient in our OLE study, further advancing the nomlabofusp clinical program and building on the successful completion of our Phase 2 dose escalation study.
  • Based on our Phase 1 and Phase 2 findings, we expect to continue daily dosing throughout the study,” said Carole Ben-Maimon, MD, President, and Chief Executive Officer of Larimar.
  • Initial data from the OLE study is expected in Q4 2024.

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

Retrieved on: 
Monday, March 11, 2024
Fast Track, Cohort, Research, Orphan drug, FDA, Cardiovascular disease, Treatment, Clinical trial, Exercise, FTD, ODD, Phenotype, Patient, Public expenditure, Hypertrophy, FXN, Heart, Cadaver, G&A, Development, FA, Pharmaceutical industry

NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease, today reported fourth quarter and full year 2023 financial results and provided operational highlights.

Key Points: 
  • Data to date suggest that FA patients may have lower FXN levels in the heart versus peripheral tissues.
  • Across all three cardiac biopsies, we observed an increase in FXN levels as measured by liquid chromatography mass spectrometry relative to pre-treatment baseline levels.
  • Lexeo anticipates the gross proceeds from the private placement to be approximately $95.0 million, before deducting any offering related expenses.
  • G&A expenses were $15.4 million for the year ended December 31, 2023, compared to $12.0 million for the same period in 2022.

First Advantage Introduces Next-Gen RightID™ to Detect Job Applicant Fraud in Pre-Hire Process

Retrieved on: 
Monday, March 11, 2024
Acquisition, Experience, Senior, Friction, Product management, Safety, HR, Organization, FBI, Machine learning, Research, FA, Online shopping

Integrated with First Advantage’s Profile Advantage® applicant platform, RightID combines multiple levels of dynamic technology to seamlessly discover inconsistencies in applicant-provided information, mitigate risks in the pre-hire process, and deliver a convenient, secure identity fraud solution to a growing problem.

Key Points: 
  • Integrated with First Advantage’s Profile Advantage® applicant platform, RightID combines multiple levels of dynamic technology to seamlessly discover inconsistencies in applicant-provided information, mitigate risks in the pre-hire process, and deliver a convenient, secure identity fraud solution to a growing problem.
  • With industry research indicating a sharp uptick in applicant fraud and stark warnings from the FBI about the use of deep fakes, employers have started to recognize emerging identity fraud concerns and the importance of fraud mitigation solutions.
  • With the comprehensive RightID solution built into existing integration workflows, employers benefit from finding potential identity fraud or likely errors in applicant data entry while keeping the hiring process fast and easy.
  • RightID offers that solution earlier in the process, without adding friction to the overall applicant experience.”
    For more information about RightID for identity fraud, visit https://fadv.com/solutions/rightid .